Working... Menu
Trial record 1 of 1 for:    NCT03102320
Previous Study | Return to List | Next Study

Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors (ARCS-Multi)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03102320
Recruitment Status : Recruiting
First Posted : April 5, 2017
Last Update Posted : August 13, 2019
ImmunoGen, Inc.
MorphoSys AG
Information provided by (Responsible Party):

No Study Results Posted on for this Study
  Recruitment Status : Recruiting
  Estimated Primary Completion Date : February 28, 2020
  Estimated Study Completion Date : July 28, 2021